Shenzhen Kexing Biotech

Kexing Biopharm (formerly Shenzhen Kexing Biotech) is a leading Chinese biopharmaceutical company specializing in the development, manufacture, and commercialization of recombinant protein drugs and microecological preparations. Founded in 1989 and headquartered in Shenzhen, the company has established a dominant market position in China with core products such as Sinogen (Interferon α1b) and Eposino (Erythropoietin). Kexing is currently transitioning toward an innovation-led model, leveraging its proprietary KX-BODY antibody and KX-FUSION protein platforms to build a robust pipeline in oncology, immunology, and degenerative diseases. Key innovative programs include GB18, a first-in-class nanobody-Fc fusion targeting GDF-15 for cancer cachexia, and GB10, a bispecific antibody for ophthalmic disorders. Listed on the Shanghai Stock Exchange (688136.SH), the company operates a global commercial network reaching over 70 countries and is committed to providing high-quality biologic medicines worldwide.